Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis

Fig. 2

CKD-506 suppresses production of tissue-degradative enzymes, inflammatory cytokines, and chemokines by fibroblast-like synoviocytes (FLS). RA FLS (n = 3) were pretreated for 1 h with CKD-506 and then activated for 24 h with IL-1β (10 ng/ml). Then, the amounts of MMP-1 (a), MMP-3 (b), IL-6 (c), IL-8 (d), CXCL10 (e), and CCL2 (f) in the supernatant were measured in an ELISA. Data represent the mean value ± SEM. *p < 0.05

Back to article page